|
 New Delhi, Oct 25 (Prensa Latina) The increasing vulnerability of the snow leopard, which is under pressure from habitat destruction and poaching, worries conservationists in India.
 Moscow, Oct 25 (Prensa Latina) The overall number of SARS-CoV-2 positive cases in Russia reached 1,513,877, following the detection of 16,710 infected in one day, Moscow's television indicated.
 Damascus, Oct 24 (Prensa Latina) Syrian health authorities on Saturday received medical assistance to fight the Covid-19 pandemic from the World Health Organization (WHO).
 Havana, Oct 23 (Prensa Latina) Ten Cuban provinces and Isla de la Juventud special municipality remain without reporting new Covid-19 cases during the last 15 days, the Ministry of Public Health (MINSAP) reported on Friday.
 Brasilia, Oct 23 (Prensa Latina) Brazilian Supreme Federal Court (STF) has ordered the Jair Bolsonaro government to draw up a new plan to fight Covid-19 in indigenous peoples, battered today with over 31,700 infections and 470 deaths.
 Photo: www.telepinar.cu
Pinar del Rio, Cuba, Oct 23 (Prensa Latina) Raul Perez, general director of the National Institute of Hygiene, Epidemiology and Microbiology, said that the most effective method to currently fight Covid-19 is people self-protection.
 London, Oct 22 (Prensa Latina) The Covid-19 vaccine candidate developed by Oxford University and Anglo-Swedish pharma AstraZeneca will continue its clinical trials in Brazil, despite the death of one of the volunteers, it was reported in London on Thursday.
 Damascus, Oct 22 (Prensa Latina) With 44 new cases, the number of Covid-19 patients reached 5,224 in Syria, the Ministry of Health informed on Thursday.
 Beijing, Oct 21 (Prensa Latina) China assured that some 60,000 volunteers have already received one of the four candidates for the coronavirus vaccine that are currently in the final phase trials, without presenting significant adverse effects.
 Beijing, Oct 20 (Prensa Latina) China reported on Tuesday that a total of 13 Covid-19 vaccine candidates are in clinical trials, four of them have entered phase III trials and no one has reported severe adverse reactions.
|
